Adalvo announces successful DCP submission of Nitrofurantoin ER 100mg capsules

Adalvo is pleased to announce that we have successfully submitted our EU DCP procedure for Nitrofurantoin ER 100mg Capsules, another differentiated product within our portfolio, that was developed based on the reference brand Macrobid.

Adalvo recognized as one of the Best Workplaces for 2021

Adalvo, one of the leading B2B global pharmaceutical companies, with commercial partnerships in more than 100 countries, have been certified as one of the Best Places to Work for 2021!

Innobic (Asia) and Aztiq co-invest in a US$475 deal to form a leading global pharma platform

The Consortium jointly, through Aztiq II HoldCo Limited, will acquire a 100% stake in Alvogen Emerging Markets Holdings Limited, thereby becoming the leading shareholders in Lotus and Adalvo.

Anil Okay is recognized as Leader of the Year by the Global Generics & Biosimilars committee

We are pleased to announce that our General Manager, Anil Okay has been awarded the Leader of the Year Award 2021, by the Global Generics & Biosimilar Awards committee.

Adalvo Announces Successful Pivotal BE Outcome Of Nintedanib 100, 150mg Soft Gel Capsules

Adalvo is delighted to announce that we successfully completed our Pivotal BE study of Nintedanib 100mg & 150mg soft gel capsules. We are now moving ahead into dossier completion, and will proceed with regulatory submission, upon exclusivity expiry.

Adalvo announces successful Pivotal BE outcome of Desmopressin 60mcg, 120mcg and 240mcg sub-lingual tablet

Adalvo is delighted to announce that we successfully completed our Pivotal BE study of Desmopressin 60mcg, 120mcg and 240mcg sub-lingual tablets. We are now moving ahead into dossier completion and will proceed with regulatory submission as soon as possible.

Adalvo announces successful DCP submission for Gralise®

We are proud to announce the successful submission of our DCP procedure for our distinguished hybrid / 505(b)(2) asset Gralise®. We expect to launch this high- value asset in H1 2023.

Adalvo announces successful DCP submission for Liraglutide pre-filled pen

We are extremely delighted to announce that we successfully submitted our DCP procedure for Liraglutide 6mg/ml pre-filled pen on Friday 29th October, which has been developed in close collaboration with one of our strategic partners.

CellResearch Corporation has been awarded an Innovation Passport for CorLiCyte™

Adalvo is delighted to announce that our partner, CellResearch Corporation (CRC), has been awarded an Innovation Passport for CorLiCyte™, by the UK’s regulatory agencies (MHRA, NICE, SMC), becoming one of only around 20 companies to receive the designation so far.

Adalvo announces successful DCP submission for Lisdexamfetamine Oral Solution

Adalvo is delighted to announce the successful submission of our DCP procedure for Lisdexamfetamine Oral Solution 10mg / ml which has been developed in close collaboration with Laboserve & Pharma-Data.

Adalvo announces successful DCP closure for Icatibant

Adalvo is pleased to announce the successful closure on our DCP procedure for our Icatibant development, a complex injectable peptide product, forming part of our high-value product portfolio offering to our partners.

Adalvo announces successful DCP filing for Teriflunomide

Adalvo is pleased to announce the successful DCP filing on its Teriflunomide development, a new addition to our high-value product portfolio offering to our partners.

Adalvo announces successful Pivotal BE outcome of Lisdexamfetamine Oral Solution 10mg / ml

Adalvo is delighted to announce the successful Pivotal BE outcome of its Lisdexamfetamine Oral Solution 10mg / mlwhich has been developed in close collaboration with Laboserve & Pharma-Data.

Adalvo announces completion of Phase III patient enrollment for Dimethyl Fumarate 30 mg / 120 mg

Adalvo is pleased to announce that we have completed our patient enrollment of our Phase 3 clinical study, to assess the safety and efficacy of Dimethyl Fumarate 30 mg / 120 mg hard capsules, which is being developed in collaboration with one of our strategic partners.

Adalvo and Hansoh Pharma enter into an exclusive license partnership

Adalvo and Jiangsu Hansoh Pharma, a leading R&D-driven pharmaceutical company in China, are pleased to announce that they have entered into an strategic partnership for the commercialization of Fulvestrant pre-filled injection in all EU markets and select Asia-Pacific markets.

Lotus Enhanced Oncology Pipeline

Adalvo is the only B2B platform with a real selected boutique approach to portfolio. We are proud to offer products from all the major pharmaceutical domains, oncology being one of them.

Adalvo submits dossier application for Enzalutamide Soft Gel Capsule 40mg

Adalvo is pleased to announce that following the successful compilation of all necessary requirements, we have submitted our dossier for Enzalutamide, and did proceed for filing via several DCP procedures in Europe.

Adalvo submits generic dossier application for Dimethyl Fumarate hard capsules

Adalvo is pleased to announce that in light of the most recent General Court decision that revoked data exclusivity protection on Dimethyl Fumarate (Tecfidera®) hard capsules, we have submitted our generic dossier application in a DCP procedure.

Teduglutide - A Unique Opportunity With Vast Orphan Market Potential

Adalvo is very excited about this unique opportunity with vast orphan market potential

Adalvo & JSC Olainfarm to launch a new urology product in 17 countries in 2022-2023

Adalvo is delighted to partner with JSC Olainfarm to launch a new product within the urology segment which is targeted to be the 1st to market opportunity in 17 countries. The prescription product will help millions of patients to regain ease and quality of life